Kristiina Maria Huttunen | Nanobiotechnology | Best Researcher Award

Posted on by ScienceFather
Assoc Prof Dr. Kristiina Maria Huttunen: Nanobiotechnology

Dr. Kristiina Maria Huttunen, born on May 7, 1980, in Taipalsaari, Finland, is an accomplished researcher specializing in drug targeting and nanochemistry. A native Finnish speaker with excellent proficiency in English, and proficiency in Swedish and basic skills in German, she is an Associate Professor at the University of Eastern Finland (UEF), leading the Transporter-mediated Drug Delivery group.

🎓 Education:

Docent Drug Targeting (Adjunct/Associate Professor): University of Eastern Finland, 2015. Ph.D. in Pharmaceutical Chemistry: University of Kuopio, 2009 (Best Thesis of the University 2008-2009). M.Sc. in Medicinal Chemistry: University of Kuopio, 2004. B.Sc. in Chemistry: University of Jyväskylä, 2003

👩‍🏫 Teaching & Continuing Education:

Course Director for Organic Chemistry (from 2023). Various teaching roles since 2005. Continued education in leadership and pedagogy.

🏢 Current Position (in Finland):

University: University of Eastern Finland. Faculty: Faculty of Health Sciences, School of Pharmacy. Position: Associate Professor (Tenure Track) and Principal Investigator (PI). Group: Leader of Transporter-mediated Drug Delivery Group (9 members). Commencement: 1st December 2023.

📚 Previous Work Experience:

Research Director, University Researcher, and Academy Research Fellow at UEF. Postdoctoral Research positions in Finland and New Zealand. Research Scientist and Ph.D. Student at the University of Kuopio.

👩‍🔬 Supervision & Teaching Experience:

Supervised numerous graduate and undergraduate students. Diverse teaching roles in organic chemistry and pharmaceutical courses.

💰 Research Funding:

PI for Project Grants totaling €3,060,733. Supervised student grants totaling €612,757. Postdoctoral and Ph.D. student grants.

👩‍💼 Institutional Responsibilities and Commissions of Trust:

Board Member, Faculty Council, and Doctoral Programme in Drug Research. Active involvement in brain barrier and brain tumor research associations. Reviewer for scientific journals and external reviewer for research plan defenses.

🔍 Scientific and Societal Impact (2004 – present):

77 Peer-reviewed original publications, 16 review articles. Invited speaker at 20 national/international conferences and seminars. Webpages and blog for open science communication. Patents and invention disclosures. Extensive engagement in general audience publications and interviews.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 2,401.
  • Citations – 1595.
  • h-index – 24.
  • Documents – 98.

A prolific researcher making meaningful contributions to the academic world!

Research Focus:

Dr. Assoc Prof Dr. Kristiina Maria Huttunen research revolves around understanding brain barrier transporters and their role in drug delivery. Their work spans the structural comparison of sulfonamide-based derivatives, exploration of experimental strategies for studying amino acid transporter utilization, and the intricate relationship between neurosteroids and organic anion transporting polypeptides (OATP)1A2.

Publications Top Note:

 

 

Prof. Funan Liu | Nanobiotechnology

Posted on by ScienceFather
Prof. Funan Liu: Oncolytic Virus

Congratulations, Prof. Funan Liu, on winning the esteemed Best Researcher Award from ScienceFather! Congratulations on reaching this significant milestone in your journey. Over the past year, you’ve undoubtedly achieved incredible feats and contributed immensely to your field. Here’s to many more years of success, innovation, and fulfillment in your endeavors. Wishing you continued growth, prosperity, and joy in the years to come. Keep shining and making a difference in the world!

Dr. Funan Liu is a distinguished medical professional, serving as a Professor, Chief Physician, and Doctoral Supervisor. Recognized as a key figure in healthcare, he holds prestigious positions as a Youth Top Talent under Liaoning Province’s ‘Revitalize Liaoning Talent Program’ and China Medical University’s Youth Top Talent. Additionally, he is a candidate in the ‘Hundred Thousand Ten Thousand Talent Project’ at the Thousand-Level. Dr. Liu serves as the Chief of the Phase I Clinical Trial Center at the First Affiliated Hospital of China Medical University. His expertise and leadership contribute significantly to advancing medical research and clinical trials, making him a prominent figure in the field.

Major academic positions:  

As the Deputy Director of the Gastric Cancer Committee for the Chinese Society for the Promotion of Health Science and Technology, Dr. Funan Liu plays a pivotal role in advancing gastric cancer research and awareness. He holds several leadership positions, including Vice Chairman of the 10th Committee of the Surgical Branch in the Liaoning Medical Association, and Standing Committee Member of various prestigious organizations, such as the Integrative Oncology Branch of the Chinese Anti-Cancer Association. Dr. Liu is actively involved in committees related to esophageal cancer, tumor prevention and control, oncology, and colorectal cancer. His extensive engagement underscores his commitment to multidisciplinary collaboration and advancing cancer care in various capacities within medical associations and committees.

Undertaken projects:

Dr. Funan Liu, a prominent researcher and medical professional, has spearheaded numerous groundbreaking projects in the realm of oncology. As a principal investigator, he led two National Key R&D Program research initiatives, focusing on clinical trials and therapeutic mechanisms of novel oncolytic virus cancer treatments, and the clinical evaluation of an in vitro tumor cell drug sensitivity technology system. Simultaneously, Dr. Liu undertook two National Natural Science Foundation of China general projects, investigating pH-sensitive liposome-hybrid red blood cell membrane-coated oncolytic virus intravenous delivery technology and the role of FN1 3’UTR as a new ceRNA in gastric cancer. His comprehensive expertise extends to projects funded by Liaoning Province and the CSCO-Merck Serono Cancer Research Fund, solidifying his impactful contributions to advancing cancer research and treatment.

Hosted and participated in clinical research:

This extensive portfolio of clinical trials reflects a commitment to advancing medical science and improving patient outcomes across various oncological fronts. Driven by cutting-edge research, these trials span from Phase I to Phase III, covering a spectrum of investigational therapies for different types of advanced solid tumors. The studies explore innovative approaches such as immunotherapy combinations, targeted therapies, and novel agents, aiming to enhance treatment efficacy and patient survival. From evaluating the safety, tolerability, and pharmacokinetics of promising compounds like TIRAGOLUMAB and DN015089 to studying the potential benefits of combining checkpoint inhibitors with chemotherapy in gastric cancer (HLX10 trial), these trials address critical gaps in current cancer care.

The diversity of trials encompasses indications like breast cancer, colorectal cancer, gastric cancer, and more, reflecting a comprehensive strategy to combat a range of malignancies. The focus on specific genetic mutations, such as EGFR in cholangiocarcinoma and bladder cancer (AL8326 trial), underscores the importance of personalized medicine in tailoring treatments to individual patient profiles. Additionally, the exploration of novel agents like BC004 injection and TJ033721 reveals a dedication to identifying and developing innovative therapeutic modalities.

These studies not only aim to expand the armamentarium of available treatments but also contribute valuable insights to the evolving landscape of cancer research. By pushing the boundaries of scientific understanding, these clinical trials under the leadership of Dr. Funan Liu hold great promise in shaping the future of oncology and, ultimately, improving the lives of patients grappling with advanced solid tumors.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 1,206.
  • Citations – 1,070.
  • h-index – 22.
  • Documents – 55.

A prolific researcher making meaningful contributions to the academic world!

Publications Top Note:
  1. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy
    • Published in Nature Communications in 2023 with 6 citations.
  2. Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus
    • Published in ACS Nano in 2023 with 0 citations.
  3. Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
  4. Inhibition of Tumor Metastasis by Liquid-Nitrogen-Shocked Tumor Cells with Oncolytic Viruses Infection
    • Published in Advanced Materials in 2023 with 4 citations.
  5. Oncolytic Virus-Driven Biotherapies from Bench to Bedside
    • Published in Small in 2023 with 2 citations.
  6. Self-assembled short peptides: Recent advances and strategies for potential pharmaceutical applications
    • Published in Materials Today in 2023 with 3 citations.
  7. Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects
    • Published in Advanced Science in 2023 with 0 citations.
  8. FN1 mRNA 3′-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3′-UTR-let-7i-5p-THBS1 axis
    • Published in Theranostics in 2023 with 0 citations.
  9. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
    • Published in Frontiers in Pharmacology in 2023 with 2 citations.
  10. Drug conjugate-based anticancer therapy – Current status and perspectives
    • Published in Cancer Letters in 2023 with 17 citations.